Tipranavir PowerPoint PPT Presentations

Tipranavir NDA 21-814: Efficacy Evaluation Rafia Bhore, Ph.D. Statistician Reviewer Division of Antiviral Drug Products Food and Drug Administration

13% females (N=108) versus 8% males (N=733) developed rash. Study 1182.52 (N=216) ... Female subjects on TPV/r have a higher frequency of rash than male counterparts ...

Tipranavir Resistance Backup Slides

Question for the Antiviral Drugs Advisory Committee. 3 ... TPV/r may increase or decrease warfarin concentrations (competing effects on CYP2C9) ...

Lack of Pharmacokinetic Interaction Between Ritonavir ... Open-label, multiple dose, three treatment, six sequence crossover study % GMR (90% CI) (n = 26) ...

1. in vitro assessment of tipranavir to inhibit cytochrome P450 ... Alprazolam. N. N. N. N. N. N. PGP. CYP3A4. CYP2D6. CYP2C9. CYP2C19. CYP1A2. Substrate. 3 ...

T-20 Resistance T-20 - first entry inhibitor - sc injection, ... New Treatments DRUG COMPANY CLASS ABS no Tipranavir Boehringer PI 104, ...

Thiazolidinediones interact with Abiraterone, Pixantrone, Azole Antifungals, Fibrates, Teriflunomide, Dabrafenib and Rifampin. Pioglitazone also interacts with Calcium channel blockers (Nifedipine, Amlodipine), Cobicistat, Piperaquine, Ifosfamide, Tolvaptan, Midazolam, Tipranavir/Ritonavir, Macrolide antibiotics, Sulphonamides, Amiodarone, Topiramate, Oral contraceptives, Atorvastatin, Danazol and Trandolapril.

HIV

Brian West: BHIVA Guidelines What s new: Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Look at new backbones of therapy?

At present, anti-HIV drugs are aimed at two targets: reverse transcriptase and HIV protease. ... Nucleoside/Nucleotide Reverse Transcriptase Inhibitors ...

Title: Lecture 7-Enzyme Inhibition-Drug Discovery Meisenberg and Simmons pp: 48-51 Author: Suriender Kumar Last modified by: suriender kumar Created Date

Effect of enzyme electric field on inhibitor. Electrostatic Energy (rigid representation... In previous studies polarization only made up 10%-30% of Eel ...

Title: actUALITZACIO ACTIVITAT 98 Author: MCG Last modified by: UsuariEstandar Created Date: 11/12/1998 1:28:04 PM Document presentation format: Presentaci n en pantalla

Glasgow HIV Conference 2006 Gus Cairns

NRTIs are sometimes called the

The patient with HIV/AIDS in intensive care Brendan McCarron HIV Outcome Now an eminently treatable condition Near normal lifespan If treated electively rather than ...

INTRODUCTORY TALK D Costagliola Chapter 1 THE CURRENT DEBATE ON ABACAVIR Study Design CV Events Effect of ABC? D:A:D[1] (N of MI = 580) Observational cohort ...

THUỐC LEDIHEP ✅ kết hợp 2 thành phần ledipasvir 90mg và sofosbuvir 400mg, điều trị viêm gan C✅LH: Nhà Thuốc Gan 0903.087.060

HIV:HCV Co-infection Landscape 21 of October, 09 Madrid,Spain GESIDA, Madrid HCV Protease Inhibitor R7227 HCV Protease Inhibitors Telaprevir and Boceprevir protease ...

... http://wwwaidsinfo.nih.gov. Initiating Antiretroviral Therapy. Acute ... TDF FTC EFV versus ZDV 3TC EFV. Study GS934. Patients (N = 517 randomized) ...

compatible PPT 97 through 2004 ... ANTIRETROVIRAL TREATMENT HIGHLIGHTS An HIV/AIDS Overview from the 44th Annual Interscience Conference on

Correctional Health Advisory Board Meeting 2000

IPCP Core C Activities Aprepitant Dose-exposure Relationship in the Monkey Jeffrey S. Barrett, Ph.D., FCP The Children s Hospital of Philadelphia

Sequential exposure to effective 'monotherapy' in a population of largely ... Virus is already dual tropic/X4. The question then becomes 'how to wait' How to Wait? ...

Inability to take regimen (or nonadherence) is one primary reason for failure of ... Consider resuming same regimen or starting new regimen and repeat resistance ...

Irreversible inhibitors bind at the active site of the enzyme and form a ... Doxycycline. competitive inhibitor of collagenase- control of periodontal disease ...

Increased Side Effects. Or will we have to wait for IFN and/or RBV sparing regimens? ... ART use at Baseline in the PARADIGM Study (US/Spain/Portugal) NRTIs ...

Interacciones que pueden aumentar el riesgo de fracaso del TARV. absorci n. metabolismo ... do not reduce atazanavir concentrations in HIV-infected patients treated ...

Maio de 1981- Duas publica es do CDC chamam a aten o para casos de Pneumonia carinii e Sarcoma de Kaposi ocorridos em LosAngeles, California, EUA

Glasgow HIV Conference 2006. Gus Cairns. GEMINI Study (saquinavir/r vs lopinavir/r) ... Other risk factors: older , other renally toxic drugs , female? HCV? ...

995 three-class experienced subjects randomized to optimized back-ground (OB) vs. ... Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy ...

Speakers Bureau: Pfizer. Research Support: Tibotec, GlaxoSmithKline, Bristol-Myers-Squibb ... This set has been peer-reviewed to ensure that there are ...

( Importance of resistance testing...) Emphasise that all PIs to be ... 7/8 had VL drop of at least 0.5 log 4 with VL below 400. Next phase sees 180 recruited ...

Mental Health & HIV/AIDS Murray Bennett, MD, FRCPC Clinical Assistant Professor Psychiatry University of Washington Director Psychiatry Madison Clinic

Update on HIV Therapy. Hail M. Al-Abdely, MD. Consultant, Infectious Diseases ... Highly active antiretroviral therapy has. Changed our view toward HIV from ...

Azole Antifungals. Amiodarone. Clarithromycin. Delavirdine. Diltiazem. Efavirenz. Erythromycin ... Azole Antifungals. Buspirone. Carbamazepine. CCB. Diltiazem ...

1996 (Vancouver): 'hit early, hit hard' Comienzo de tratamiento ... Contributing patients, n. 33. 32. 32. 31. Double Blind. Only. Double Blind. and. Open Label ...

Serious and/or life threatening peripheral ischemia has been associated with the ... Hence, concomitant use of these medications is contraindicates (See also ...

The incidence is around the general incidence of hepatotoxicity with HAART therapy, about 6%. Ritonavir appears to be higher, and indinavir can cause hyperbilirubinemia.

Idibaps-Hospital Cl nic i Universitari. Barcelona. 27 de Noviembre ... and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159:2221-2224. ...

2nd leading cause of disease burden worldwide. Leading cause of death ... Oral hairy leukoplakia. Aphthous ulcers. Herpes simplex. Gingivitis. Kaposi's sarcoma ...

Clinical Director, Northwest AIDS Education and Training Center ... 4. Valacyclovir (Valtrex) DHS/HIV/PP. DHS/HBV/PP. FDA-Approved Therapies for HBV Infection ...

Obliga a las O. Sociales a la cobertura de tratamientos m dicos, psicol gicos y ... Argentina tiene una epidemia concentrada y las tasas de incidencia siguen ...

Boosted protease inhibitors have 60% lower risk of resistance compared with ... Ritonavir boosted regimens are widely used but the best results are usually ...

Activo frente a VIH con multirresistencia a ITIAN (mutaci n 151) ... Perfil de resistencias similar a 3TC, activo frente al VIH y VHB ...

Undetectables 2006: Seminario Nadir Onlus Nuovi farmaci e nuove formulazioni: update scientifico Simone Marcotullio 24 Marzo 2006 Molecole: 4 classi in commercio nel ...

Resistance mutations may become minor species in the absence of selective drug pressure. ... Prefer at least 2 fully active agents to design a new regimen ...

Antiviral Drugs The final stage in the life cycle of a virus is the release of completed viruses from the host cell, and this step has also been targeted by antiviral ...

Professor of Medicine, David Geffen School of Medicine at UCLA ... tubulointerstitial nephritis with medullary calcification and cortical atrophy ...

Division of Infectious Diseases and International Medicine ... Polypharmacy. Drug-interactions. Renal Disease. Dose modifications. Contraindicated agents ...

ANTIVIRAL AGENTS Dr. Roshna Sh. Aziz Department of Pharmacology School of medicine University of sulaimani The marked increase in the prevalence of resistance to both ...

... Entry inhibitors Enfuvirtide (fusion inhibitor); Maraviroc (CCR5 receptor antagonist); Drugs for Viral Hepatitis Interferons , , ...

Clinical History: A 36 year-old HIV-positive male patient presented with extensive scaly hypo-pigmented lesions over his face and body. ... Source: GHTM, Chennai, ...

Antiviral Drugs General Characteristics of Viruses Depending on one's viewpoint, viruses may be regarded as exceptionally complex aggregations of nonliving chemicals ...

Overcoming Treatment Challenges in the Treatment-Experienced Patient With HIV A ... 1. Fundaci n Huesped, Buenos Aires, Argentina; 2. Duke University, Durham, NC, USA ...